234 related articles for article (PubMed ID: 17145840)
1. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
2. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.
Guminski AD; Balleine RL; Chiew YE; Webster LR; Tapner M; Farrell GC; Harnett PR; Defazio A
Gynecol Oncol; 2006 Feb; 100(2):239-46. PubMed ID: 16213010
[TBL] [Abstract][Full Text] [Related]
3. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
Materna V; Pleger J; Hoffmann U; Lage H
Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
[TBL] [Abstract][Full Text] [Related]
4. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.
Materna V; Stege A; Surowiak P; Priebsch A; Lage H
Biochem Biophys Res Commun; 2006 Sep; 348(1):153-7. PubMed ID: 16876126
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
6. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
[TBL] [Abstract][Full Text] [Related]
7. Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2.
Materna V; Holm PS; Dietel M; Lage H
Cancer Gene Ther; 2001 Mar; 8(3):176-84. PubMed ID: 11332988
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
Liedert B; Materna V; Schadendorf D; Thomale J; Lage H
J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
[TBL] [Abstract][Full Text] [Related]
10. ISG15 suppresses translation of ABCC2 via ISGylation of hnRNPA2B1 and enhances drug sensitivity in cisplatin resistant ovarian cancer cells.
Wang JM; Liu BQ; Zhang Q; Hao L; Li C; Yan J; Zhao FY; Qiao HY; Jiang JY; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118647. PubMed ID: 31926942
[TBL] [Abstract][Full Text] [Related]
11. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
[TBL] [Abstract][Full Text] [Related]
13. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
15. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
Nakayama K; Kanzaki A; Ogawa K; Miyazaki K; Neamati N; Takebayashi Y
Int J Cancer; 2002 Oct; 101(5):488-95. PubMed ID: 12216079
[TBL] [Abstract][Full Text] [Related]
16. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Haenisch S; Zimmermann U; Dazert E; Wruck CJ; Dazert P; Siegmund W; Kroemer HK; Warzok RW; Cascorbi I
Pharmacogenomics J; 2007 Feb; 7(1):56-65. PubMed ID: 16788565
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. Ezrin and radixin both regulate the apical membrane localization of ABCC2 (MRP2) in human intestinal epithelial Caco-2 cells.
Yang Q; Onuki R; Nakai C; Sugiyama Y
Exp Cell Res; 2007 Oct; 313(16):3517-25. PubMed ID: 17825285
[TBL] [Abstract][Full Text] [Related]
19. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
20. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
